Background: Hypothermia, either therapeutically induced or accidental (ie, an involuntary decrease in core body temperature to <35°C), results in hemostatic disorders.
| INTRODUC TI ON
Platelet activation influences hemostasis and prevents severe bleeding. However, overactivation of platelets often causes thrombotic disease. Hence, platelet activation is tightly controlled under physiological conditions. Platelet homeostasis is sensitive to low temperatures, 1, 2 and the rate of platelet activation increases when platelet-rich plasma is stored at 4°C. 3, 4 Furthermore, transfusion of platelet-rich plasma stored at 4°C enhances beneficial clotting activity. [5] [6] [7] Various mechanisms have been proposed to explain this coldinduced platelet activation. [8] [9] [10] [11] [12] [13] Both in vitro and in vivo exposure to low temperatures alter platelet activity and hemostasis; this hypothermia can be therapeutically induced or accidental. Although mild therapeutic hypothermia is a standard treatment component for patients resuscitated from cardiac arrest, 14, 15 it also causes coagulation disorders. 16, 17 For example, platelet degranulation and dysfunction are triggered by intraoperative hypothermic circulatory arrest. 18, 19 In contrast to therapeutic hypothermia, accidental hypothermia is an involuntary decrease in core body temperature to <35°C due to exposure to snow, wind, water, or high altitude. Accidental hypothermia is classified as mild (core temperature 32°C-35°C), moderate (28°C-32°C), or severe (<28°C). 20 In therapeutic or accidental hypothermia, although platelets are not exposed to a temperature as low as 4°C, coagulation disorders are induced by body temperatures of 28°C-35°C. [14] [15] [16] [17] [18] [19] [20] The mechanism of hypothermia-induced platelet activation and hemostasis is controversial, with two conflicting mechanisms proposed. The first suggests that hypothermia promotes platelet margination via an increasing hematocrit, which changes platelet shape, reduces blood flow, and increases the expression of adhesion molecules, resulting in thrombosis. 21 The second suggests that hypothermia inhibits the enzymatic activities involved in the coagulation cascade. 22 Indeed, case studies show that hypothermia induces both a hypercoagulable state and a hemorrhagic tendency. 23, 24 Thus, it remains unclear whether hypothermia enhances or inhibits coagulation.
During therapeutic hypothermia, the body temperature reduction is gradual and is closely monitored and controlled [25] [26] [27] ; thus, the alteration of platelet function is normally reversible after the hypothermic state is reversed. 4, 28, 29 Conversely, in accidental severe hypothermia, the decrease in body temperature may be rapid and more severe, and the progression and reversibility of hypothermia vary depending on the situation, making the pathophysiological details more difficult to understand. To investigate platelet bioactivity and hemostasis during deep hypothermia, we considered animal models to be more suitable than clinical observations. The characterization of molecular dynamics in thrombosis and hemostasis during hypothermia will contribute to the development of treatment protocols for accidental hypothermia. In the present study, we investigated the platelet and clotting activities in deep hypothermia in a mouse model.
| MATERIAL S AND ME THODS

| Animal models
The experimental procedures were approved by the animal experiments committee of Asahikawa Medical University, and all other methods were performed in accordance with the relevant guidelines and regulations. We divided 8-week-old male C57Bl/6 mice into six groups (n = 10 in each group; Figure 1 sodium citrate solution in a 9:1 ratio.
| Histopathological analysis
Formalin-fixed, paraffin-embedded tissue samples were prepared in accordance with a standard protocol. We performed immunohistochemical staining for CD62P as a marker of activated platelets, and for CD61 as a marker of total platelets. For the immunohistochemical analysis, 3-μm-thick paraffin sections were sequentially treated before application with the primary antibody in the following way: deparaffinization, rehydration, quenching of endogenous peroxidase, and antigen retrieval. Sections were then incubated with primary antibody for CD62P (Novus Biologicals, Littleton, CO) or anti-CD61 (Cell Signaling Technology, Danvers, MA), followed by detection with horseradish peroxidase-conjugated secondary antibody for mice or rabbits (Vector Labs, Burlingame, CA). The CD62P-positive area in splenic red pulp was quantified. Representative pictures of the splenic red pulp from each mouse were taken under ×400 magnification. After obtaining each CD62P-positive area (square micrometers) using ImageJ software, the ratio of each area to the average area in C-mice was calculated. Martius Scarlet Blue staining was performed to detect microthrombi. 30 The percentage of thrombus-positive renal glomeruli with respect to the total number of renal glomeruli (one kidney section contains approximately 150 glomeruli) was counted in each kidney under ×400 magnification. 
| Complete blood cell count and flow cytometry
| Scanning electron microscopy
Splenic tissue samples were fixed in 2.5% glutaraldehyde, cut into small blocks, and fixed in 1% osmium for 1 h. The samples were then processed via sequential alcohol dehydration and infiltrated with t-butyl alcohol. After freezing, the tissues were vacuum-dried and coated with ion sputter (Hitachi E-1030; Hitachi, Tokyo, Japan) for analysis with a scanning electron microscope (SEM S-4100; Hitachi).
| Coagulation assay
Prothrombin time (PT) and activated partial thromboplastin time (APTT) were analyzed using an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA). 31
| Enzyme-linked immunosorbent assay
Pro-platelet basic protein (PPBP), platelet factor 4 (PF4), von
Willebrand Factor (vWF), and D-dimer levels were analyzed using enzyme-linked immunosorbent assay (ELISA) kits from Abcam (Cambridge, UK) for PPBP, R&D Systems (Minneapolis, MN) for PF4, and LifeSpan BioSciences (Seattle, WA) for vWF and D-dimer.
| Real-time polymerase chain reaction
Total RNA was isolated from the spleen and reverse transcribed. Realtime polymerase chain reaction (RT-PCR) was performed using the ABI
system (Thermo Fisher Scientific) with TaqMan probes for mouse
Vwf messenger RNA (mRNA), and for 18S ribosomal RNA as an internal control. Each threshold cycle was obtained, and the double-delta threshold cycle method was used to calculate the expression values.
| Western blot analysis
The tissue samples underwent lysis in SDS-buffer and separation in polyacrylamide-sodium dodecyl sulfate (SDS) gel and were electrotransferred to nitrocellulose membranes. The membranes were then probed with rabbit anti-vWF (Abcam) or mouse anti-Actin antibody (BD Bioscience). The membranes were incubated with the respective horseradish peroxidase-conjugated antirabbit or antimouse immunoglobulin G secondary antibodies (R&D Systems). Antibody binding was visualized using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). The quantification was performed by densitometric measurement using ImageJ software.
| Statistical analysis
The differences in the experimental values were analyzed via the Student paired t test or one-way analysis of variance followed by the Tukey-Kramer method.
| RE SULTS
| Platelet status in the spleen
There were only two or three CD62P-positive platelet adhesions per blood vessel in the liver, kidneys, heart, lungs, and skin of C-mice and H-mice ( Figure 2A ). The splenic red pulp of H-mice had a 7-fold increase in the area of CD62P-positive platelet adhesions compared with C-mice, but no significant difference in the amount of CD61-positive platelets ( Figure 2B ). H-mice spleens contained platelets with extended pseudopods ( Figure 2C ). The plasma levels of PPBP and PF4 (biomarkers of platelet degranulation) were significantly higher in H-mice compared with C-mice ( Figure 2D ). 
| Platelet status in the peripheral blood
The trapping of aberrant or aged platelets flowing in the peripheral blood is an important role of splenic red pulp. We, therefore, tried to ascertain whether the appearance of activated platelets in the spleen was due to aberrant activation of platelets in the peripheral blood. Complete blood count revealed no significant differences between C-mice and H-mice in the PLT, platelet distribution width, mean platelet volume, platelet large cell ratio, or plateletcrit ( Figure 3A ). Furthermore, flow cytometry for the detection of CD62P/CD61 double-positive platelets in the peripheral blood did not reveal any significant differences between C-mice and H-mice ( Figure 3B ).
| The importance of the splenic tissue environment in hypothermia-induced platelet activation
The results discussed suggested that the platelets that were physiologically pooled in the splenic red pulp might be activated in hypothermic mice. To clarify whether platelet activation was confined to the spleen in hypothermic mice, we performed the hypothermic experiments using splenectomized mice (SNC-mice and SNH-mice). Complete blood count revealed no significant differences between SNC-mice and SNH-mice in the number or morphology of peripheral platelets ( Figure 4A ). Flow cytometry for CD62P/CD61 double-positive platelets in the peripheral blood revealed no significant difference between SNC-mice and SNH-mice ( Figure 4B ). Immunohistochemical staining for CD62P revealed only a few platelet adhesions in the liver, kidneys, heart, lungs, and skin of splenectomized mice ( Figure 4C ). Additionally, there were no significant differences in the plasma PPBP and PF4 levels of SNC-mice versus SNH-mice ( Figure 4D ). Figure 5A) . Similarly, Western blot analysis revealed that the vWF protein expression was elevated in the spleens of H-mice compared with C-mice ( Figure 5B ). There was significant elevation of vWF protein expression in the spleens of H-mice versus C-mice, while similar elevations were not observed in the lungs, liver, and kidneys ( Figure 5C ). In addition, ELISA demonstrated that H-mice had significantly higher plasma vWF levels than C-mice ( Figure 5C ). However, the plasma vWF levels of SNH-mice did not significantly differ from those of SNC-mice ( Figure 5C ).
| von Willebrand factor expression in the spleen and plasma under hypothermic conditions
| Coagulation and fibrinolysis in hypothermic mice
To assess whether the platelet degranulation in the spleen affected the coagulation and fibrinolysis, we evaluated the D-dimer level (fibrin degradation products), PT, and APTT. There was no significant difference in the plasma D-dimer level of H-mice versus C-mice ( Figure 6A ). Although the PT did not significantly differ between Cmice and H-mice, the APTT was significantly prolonged in H-mice and SNH-mice compared with C-mice and SNC-mice, respectively ( Figure 6B ).
| Hypercoagulation status after rewarming
Twenty-four hours after rewarming, plasma D-dimer concentrations were increased in HR-mice, but not in SNHR-mice ( Figure 7A ).
Martius Scarlet Blue staining revealed microthrombi in the glomeruli of HR-mice (an average of 2.3% of glomeruli contained thrombi in five mice) but not in C-mice, SNC-mice, and SNHR-mice ( Figure 7B) . The APTT and PT were prolonged in HR-mice, but not in SNHR-mice ( Figure 7C ). 
| D ISCUSS I ON
Previous studies report platelet sequestration in the spleen and liver along with peripheral platelet reduction in hypothermic animals. 32, 33 However, the biological significance of these phenomena and the function of platelets in this specific context remain unclear.
Furthermore, these previous studies involved relatively mild hypothermic conditions. 32, 33 In the present study, we exposed the mice to severe hypothermia and discovered new information about platelet activity in hypothermia. The mice exposed to deep hypothermia had an abundance of CD62P-positive activated platelets in the splenic red pulp, while the amount of CD61-positive platelets was unchanged. Moreover, the plasma PPBP and PF4 levels increased after exposure to low temperatures, indicating platelet degranulation; however, the peripheral platelet parameters (PLT, mean platelet volume, platelet distribution width, and number of CD62P/CD61 double-positive platelets) did not significantly differ from thyose of control mice. Furthermore, the plasma PPBP and PF4 levels did not increase in splenectomized mice after exposure to low temperatures, indicating that the splenic tissue environment was necessary for hypothermia-induced platelet activation. One-third of the platelets are stored in the spleen under physiological conditions. 34 Thus, our findings suggest that severe hypothermia did not affect peripheral platelets but caused activation and the degranulation of the platelets physiologically pooled in the splenic red pulp.
Although several other studies showed a reduction in the peripheral platelets after hypothermia, 32, 33 we did not observe this phenomenon. This discrepancy may be due to the difference between studies in the severity of hypothermia. In our severe hypothermia model, the body core temperature was markedly decreased, while the other studies used only a mild reduction in body temperature. We kept the mice at −20°C under general anesthesia to mimic severe accidental hypothermia in humans. It took approximately 1 h for the rectal temperature of the mice to decrease to 15°C. We then collected the peripheral blood samples immediately after the rectal temperatures decreased to 15°C, as it was difficult to keep the mice alive past this timepoint. We hypothesize that this short period of severe hypothermia was not long enough to cause splenic platelet sequestration, but that the activation of the platelet pool in the spleen occurred prior to the sequestration of peripheral platelets.
Many reports have described the interactions between vWF and platelet receptors, glycoprotein Ib-IX-V, and αIIbβ3 integrin-promoted primary platelet adhesion and aggregation. [35] [36] [37] [38] In our splenic tissue analysis, hypothermia enhanced vWF expression in both mRNA and Upon activation, platelets release various substances from their intracellular granules that contribute to coagulation. [39] [40] [41] [42] [43] [44] For example, plasma PPBP and PF4 reportedly activate coagulation. [45] [46] [47] [48] Although we suspect that these substances were released into the plasma of hypothermic mice, we did not detect significant thrombosis or plasma D-dimer elevation in mice euthanized immediately after the hypothermia treatment. This suggests that platelet activation in the hypothermic spleens did not cause thrombosis when the body temperature was low, even when active platelet-derived substances were released into the plasma.
Some clinical observations have demonstrated that low temperatures cause prolonged PT and APTT. 49, 50 We also observed prolonged APTT in the plasma collected from mice immediately after the hypothermia treatment, regardless of the presence or absence of splenic tissue where the platelets were being activated, indicating that the hypothermia itself inhibited the intrinsic pathway of the coagulation cascade. Some in vitro studies have shown that cold storage of plasma results in the reduction of coagulation factors. [51] [52] [53] However, the impact of body temperature reduction on each coagulation factor needs further investigation.
The rewarmed non-splenectomized mice had an increased plasma D-dimer concentration and microthrombosis in renal glomeruli, indicating a hypercoagulable state; these changes were not observed in the rewarmed asplenic mice. The rewarmed non-splenectomized mice also had prolonged PT and APTT, while the rewarmed asplenic mice did not. As the prolongation of PT and APTT in the rewarmed non-splenectomized mice was accompanied by D-dimer elevation and microthrombosis, this suggests that the coagulation factors had been consumed. Furthermore, these observations indicate that the coagulation substances released by platelets during hypothermia in the spleen upregulated the coagulation cascade and resulted in microthrombosis when the body was rewarmed. Presumably, the activity of coagulants released during platelet degranulation was inhibited when the body temperature was low but was reactivated by rewarming.
In conclusion, the main findings of the present study were that severe hypothermia increased vWF production in the spleen, which induced platelet activation and degranulation. This phenomenon resulted in microthrombosis when the body was rewarmed. Our results provide novel information, indicating that the activation of platelets in the splenic pool is the key biological event in the hypothermia-induced hypercoagulable state. Irrespective of whether hypothermia is therapeutic or accidental, rewarming is necessary for recovery. Therefore, it is important to keep in mind that platelet activation in the splenic pool leads to microthrombosis upon rewarming.
